What Frequency Therapeutics does

Frequency Therapeutics is a clinical-stage biotechnology company founded in 2015 and based in Lexington, Massachusetts, that develops small-molecule drugs intended to activate progenitor cells in vivo to restore damaged or degraded tissue. Its core technical premise is the proprietary activation of resident progenitor-cell populations, with publicly disclosed therapeutic exploration spanning sensorineural hearing loss (its flagship program), type 1 diabetes (under a 2018 partnership-style funding from Breakthrough T1D), and additional indications supported by a 2018 grant from the U.S. Department of War.

The company historically generated revenue through milestone-driven collaboration and grant arrangements rather than product sales, with reported top lines of roughly $37M in 2020 and $14M in 2021 before ceasing disclosure in 2022. Across the 2018-2022 period the company raised approximately $180M+ in cumulative disclosed equity and grant funding from a mix of specialist biotech investors (Perceptive Advisors, RTW Investments, Wasatch Advisors) and strategic backers (Taiwania Capital, Korea Investment Partners, Yonjin Venture), alongside non-dilutive awards from the U.S. Department of War and Breakthrough T1D.

Operating losses exceeded $80M in both 2021 and 2022, headcount is reported at 11-50 employees, the company is listed as delisted from NASDAQ (symbol FREQ), and its corporate website is currently unreachable (HTTP 522). These signals collectively indicate the company has materially contracted from its pre-2022 operating scale and is no longer functioning as an active commercial biotech.

Name

Frequency Therapeutics

Website

https://frequencytx.com

Company type

Private

Founded year

2015

Headcount range

11–50 employees

Short description

Frequency Therapeutics is a Lexington, Massachusetts-based, now-delisted clinical-stage biotech developing small-molecule drugs designed to activate progenitor cells to regenerate damaged tissue across hearing loss and other indications.

Ownership category

akta.pro rank

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Frequency Therapeutics develops small molecule drugs designed to activate progenitor cells within the body to restore healthy tissue. The company's lead therapeutic approach targets hearing loss through regeneration of inner ear hair cells, leveraging its proprietary Progenitor Cell Activation (PCA) platform to create disease-modifying treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• FX-322

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights3 records

Direct peers

• Pipeline Therapeutics: Clinical-stage biotech developing small-molecule therapeutics that target neural progenitor cell biology for hearing loss and remyelination — overlapping mechanism (small-molecule progenitor activation) and overlapping indications (MS) with Frequency's post-pivot focus.
• Contineum Therapeutics: Small-molecule developer with a clinical program in progressive MS and remyelination (VSA-001 / PIPE-307) — directly comparable to Frequency's FX-001 in modality, target biology, and patient population.
• Decibel Therapeutics: Pre-acquisition, Decibel Therapeutics pursued small-molecule and gene-therapy approaches to hearing restoration — the same indication Frequency's FX-322 targeted prior to its divestiture to Astellas.
• Otonomy: Clinical-stage company developing therapeutics for ear disorders and hearing loss — historically a direct competitor to Frequency's FX-322 program in otology indications.
• Auris Medical: Clinical-stage company developing therapeutics for inner-ear and hearing disorders — a direct historical peer in the otology space where Frequency operated prior to its FX-322 failure.

Emerging players

• Athersys: Cell-therapy and regenerative-medicine developer (MultiStem) targeting neurological and inflammatory indications — shares Frequency's regenerative-medicine thesis and small-cap clinical-stage risk profile.
• Lineage Cell Therapeutics: Cell-replacement and regenerative-medicine company developing allogeneic cell therapies for CNS indications — comparable in regenerative-medicine modality and clinical-stage CNS focus to Frequency's remyelination effort.
• VistaGen Therapeutics: Small clinical-stage CNS-focused biotech developing small-molecule therapeutics — comparable in scale, stage, and CNS-focused small-molecule positioning to Frequency's post-pivot profile.

Broad incumbents

• Acadia Pharmaceuticals: CNS-focused commercial-stage biopharma with a neurological-disease pipeline — a broader incumbent illustrating the strategic and clinical benchmarks Frequency's CNS remyelination program must reach to compete for adoption.
• Vertex Pharmaceuticals: Large-cap biopharma pursuing small-molecule approaches to serious diseases (including cell/gene editing for sickle cell and beta-thalassemia) — sets the gold standard for small-molecule regenerative-medicine execution that Frequency aspires to.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/frequencytx
• LinkedInlinkedin.com/company/frequency-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds8 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frequency Therapeutics